Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2013; 19(21): 3309-3315
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3309
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3309
Figure 1 Overall survival analysis according to the Kaplan-Meier method for patients in the surgery only group (n = 634), the capecitabine and oxaliplatin group (n = 214) and the 5-fluorouracil, folinic acid and oxaliplatin group (n = 48).
Overall survival was higher in the capecitabine and oxaliplatin (XELOX) group vs the surgery only group (P = 0.069) and 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX6) groups (P = 0.022).
- Citation: Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315
- URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3309.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i21.3309